Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CKPT NASDAQ:SVRA NASDAQ:TFFP NASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCKPTCheckpoint Therapeutics$4.26$4.23$2.06▼$4.50$370.71M1.181.56 million shsN/ASVRASavara$3.62+0.4%$2.98$1.89▼$4.70$623.08M0.561.28 million shs583,375 shsTFFPTFF Pharmaceuticals$0.07$0.06$0.06▼$3.23$289KN/AN/AN/ATRVITrevi Therapeutics$8.52-0.2%$7.52$2.36▼$9.92$1.03B0.711.96 million shs392,129 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCKPTCheckpoint Therapeutics0.00%0.00%0.00%0.00%+73.17%SVRASavara0.00%+0.28%+18.03%+74.76%-18.92%TFFPTFF Pharmaceuticals0.00%0.00%0.00%0.00%-97.15%TRVITrevi Therapeutics+7.02%-12.41%+16.67%+43.29%+150.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCKPTCheckpoint Therapeutics$4.26$4.23$2.06▼$4.50$370.71M1.181.56 million shsN/ASVRASavara$3.62+0.4%$2.98$1.89▼$4.70$623.08M0.561.28 million shs583,375 shsTFFPTFF Pharmaceuticals$0.07$0.06$0.06▼$3.23$289KN/AN/AN/ATRVITrevi Therapeutics$8.52-0.2%$7.52$2.36▼$9.92$1.03B0.711.96 million shs392,129 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCKPTCheckpoint Therapeutics0.00%0.00%0.00%0.00%+73.17%SVRASavara0.00%+0.28%+18.03%+74.76%-18.92%TFFPTFF Pharmaceuticals0.00%0.00%0.00%0.00%-97.15%TRVITrevi Therapeutics+7.02%-12.41%+16.67%+43.29%+150.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCKPTCheckpoint Therapeutics 2.33Hold$4.331.72% UpsideSVRASavara 2.83Moderate Buy$7.50107.47% UpsideTFFPTFF Pharmaceuticals 0.00N/AN/AN/ATRVITrevi Therapeutics 3.13Buy$21.75155.28% UpsideCurrent Analyst Ratings BreakdownLatest SVRA, CKPT, TRVI, and TFFP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025SVRASavaraGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $11.009/8/2025SVRASavaraOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$6.00 ➝ $8.009/3/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $8.008/21/2025TRVITrevi TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$18.008/15/2025SVRASavaraOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$5.00 ➝ $6.008/15/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$2.00 ➝ $5.008/8/2025TRVITrevi TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetStrong-Buy$29.00 ➝ $27.008/8/2025TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$24.00 ➝ $22.007/1/2025TRVITrevi TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCKPTCheckpoint Therapeutics$41K9,041.59N/AN/A($0.47) per share-9.06SVRASavaraN/AN/AN/AN/A$1.00 per shareN/ATFFPTFF Pharmaceuticals$730K0.40N/AN/A$4.04 per share0.02TRVITrevi TherapeuticsN/AN/AN/AN/A$1.30 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCKPTCheckpoint Therapeutics-$51.85M-$1.29N/A∞N/AN/AN/A-659.07%N/ASVRASavara-$95.88M-$0.50N/AN/AN/AN/A-69.05%-54.84%11/11/2025 (Estimated)TFFPTFF Pharmaceuticals-$21.24M-$6.44N/A∞N/AN/AN/AN/AN/ATRVITrevi Therapeutics-$47.91M-$0.42N/AN/AN/AN/A-41.44%-38.21%11/5/2025 (Estimated)Latest SVRA, CKPT, TRVI, and TFFP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q1 2025SVRASavara-$0.12-$0.14-$0.02-$0.14N/AN/A8/7/2025Q2 2025TRVITrevi Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCKPTCheckpoint TherapeuticsN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCKPTCheckpoint TherapeuticsN/A0.290.29SVRASavara0.2511.0811.08TFFPTFF PharmaceuticalsN/AN/AN/ATRVITrevi TherapeuticsN/A22.4222.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCKPTCheckpoint Therapeutics22.00%SVRASavara87.93%TFFPTFF Pharmaceuticals15.25%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipCKPTCheckpoint Therapeutics2.10%SVRASavara5.33%TFFPTFF Pharmaceuticals4.50%TRVITrevi Therapeutics18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCKPTCheckpoint Therapeutics1087.02 million47.81 millionOptionableSVRASavara20172.84 million163.63 millionOptionableTFFPTFF Pharmaceuticals194.44 million4.24 millionOptionableTRVITrevi Therapeutics20121.78 million99.49 millionOptionableSVRA, CKPT, TRVI, and TFFP HeadlinesRecent News About These CompaniesTrevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025September 18 at 7:30 AM | prnewswire.comTrevi Therapeutics (NASDAQ:TRVI) Shares Down 4.6% - Should You Sell?September 14, 2025 | marketbeat.comTrevi Therapeutics, Inc. $TRVI Shares Sold by Woodline Partners LPSeptember 14, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Sees Strong Trading Volume - Still a Buy?September 13, 2025 | marketbeat.comFred Alger Management LLC Invests $482,000 in Trevi Therapeutics, Inc. $TRVISeptember 13, 2025 | marketbeat.comSiren L.L.C. Sells 42,267 Shares of Trevi Therapeutics, Inc. $TRVISeptember 13, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month High - Should You Buy?September 12, 2025 | marketbeat.comBrokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $21.75September 12, 2025 | americanbankingnews.comHaduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan StanleySeptember 11, 2025 | msn.comTrevi Therapeutics, Inc. $TRVI Stock Position Raised by Acorn Capital Advisors LLCSeptember 11, 2025 | marketbeat.comExome Asset Management LLC Takes $1.03 Million Position in Trevi Therapeutics, Inc. $TRVISeptember 11, 2025 | marketbeat.comOctagon Capital Advisors LP Makes New $20.90 Million Investment in Trevi Therapeutics, Inc. $TRVISeptember 11, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of "Buy" by AnalystsSeptember 11, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Trading 8.9% Higher - Here's WhySeptember 10, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Reduces Holdings in Trevi Therapeutics, Inc. $TRVISeptember 10, 2025 | marketbeat.comTrevi Therapeutics, Inc. (TRVI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9, 2025 | seekingalpha.comPolar Asset Management Partners Inc. Acquires Shares of 64,050 Trevi Therapeutics, Inc. $TRVISeptember 9, 2025 | marketbeat.comTrevi Therapeutics, Inc. $TRVI Stock Holdings Boosted by Cubist Systematic Strategies LLCSeptember 9, 2025 | marketbeat.comTrevi Therapeutics, Inc. $TRVI Holdings Lifted by Raymond James Financial Inc.September 9, 2025 | marketbeat.comAlly Bridge Group NY LLC Sells 95,270 Shares of Trevi Therapeutics, Inc. $TRVISeptember 5, 2025 | marketbeat.comTrevi Therapeutics, Inc. $TRVI Stock Position Lifted by Panagora Asset Management Inc.September 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSVRA, CKPT, TRVI, and TFFP Company DescriptionsCheckpoint Therapeutics NASDAQ:CKPTCheckpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.Savara NASDAQ:SVRA$3.62 +0.02 (+0.42%) As of 11:10 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.TFF Pharmaceuticals NASDAQ:TFFPTFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.Trevi Therapeutics NASDAQ:TRVI$8.52 -0.02 (-0.23%) As of 11:10 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Joby's Stock Is Quiet, But Its Commercial Engine Is In Overdrive Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
